Pregnancy is an opportune time to identify opioid dependence, facilitate conversion to opioid maintenance treatment, and coordinate care with specialists in addiction medicine, behavioral health, and social services. Comprehensive prenatal care for opioid-dependent women involves the evaluation and the management of co-occurring psychiatric disorders, polysubstance use, infectious diseases, social stressors, and counseling regarding the importance of breastfeeding, contraception, and neonatal abstinence syndrome. Although the complex psychiatric, social, and environmental factors faced by this population pose significant challenges to obstetric care providers, the development of strong patient-provider relationships can facilitate the ability to deliver efficient and effective health care during pregnancy.
Introduction
Opioid abuse has increased drastically over the last decade and accounts for a significant portion of drugs misused during pregnancy. From 2000 through 2009, the incidence of maternal opioid use during pregnancy increased from 1.19 to 5.77 per 1000 hospital live births per year. 1 Correspondingly, the rate of neonatal abstinence syndrome (NAS) or neonatal drug withdrawal after birth has also increased substantially from 1.20 to 3.39 per 1000 hospital live births per year. 1 The management and the treatment of substance use disorders and, specifically, 370 | www.clinicalobgyn.com opioid dependence during pregnancy is a challenging and complex process that requires involvement and investment from a multidisciplinary team of health care providers. Obstetric care providers have a unique opportunity to make a substantive impact on the lives of opioid-dependent (OD) women and their children by providing a medical home for patients during pregnancy, facilitating care coordination among providers, and delivering comprehensive prenatal and postpartum care.
Maternal and Neonatal Effects of Opioid Dependence
Approximately 30% of the pregnancies complicated by opioid dependence end in preterm birth (<37 wk), a rate that is 3 times the national average. 2, 3 Neonates born to OD women are more likely to be low birth weight (<2500 g), admitted to the neonatal intensive care unit, and require prolonged treatment for NAS. 4, 5 NAS, a drug withdrawal syndrome after birth, affects 45% to 94% of the infants born to OD mothers, results in significant neonatal morbidity, and requires the intensive use of health care resources. [5] [6] [7] [8] Average hospital costs for infants with NAS are $53,400 in comparison with $9500 for all other hospital births. 1 Over 35% of OD pregnant women screen positive for additional drugs such as marijuana, cocaine, and benzodiazepines on urine drug screens, and tobacco smoking rates range from 77% to 95%. [9] [10] [11] [12] OD pregnant women are also at an increased risk of having a coexisting psychiatric diagnosis such as depression, anxiety, bipolar affective disorder, personality disorders, and posttraumatic stress disorder. [13] [14] [15] OD women are frequently raised in a family environment complicated by substance abuse, are often drawn into substance use by partners (ie, contagion), and have a history of victimization related to physical and sexual violence. OD women are also more likely to use drugs with multiple partners and exchange sex for drugs than men. [16] [17] [18] Because of the high rate of intravenous opioid use and sex-related risk patterns, 50% to 62% of the OD women are hepatitis C virus (HCV) positive and 1% to 4% are HIV positive. 19, 20 
Antepartum Care and Management
Pregnancy is a unique opportunity to identify opioid dependence, facilitate conversion to opioid maintenance treatment, and coordinate care among specialists in addiction medicine, behavioral health, and social services. 21 OD pregnant women should receive all elements of routine pregnancy care, but may benefit from more frequent prenatal care visits to address complex psychosocial needs as well as facilitate referrals to social services and case management to address long-term needs after delivery. Increased eligibility for Medicaid during pregnancy and the postpartum period also facilitates access to opioid replacement therapy, prenatal care, and other necessary health care services for many otherwise uninsured high-risk women. Although there are no clear guidelines for antenatal testing, consideration can be given to monthly ultrasound assessments of fetal growth from 24 weeks' gestation due to an increase in the risk of low-birthweight infants in women on methadone maintenance therapy. 22 Weekly antenatal testing initiated at 32 weeks may also be considered due an increased risk of fetal demise. 22, 23 In the absence of other medical indications, more intensive medical care or a referral to a maternal-fetal medicine specialist is not necessary. 21 
SCREENING FOR SUBSTANCE USE
The American College of Obstetricians and Gynecologists recommends that all women be screened for the use of drugs and/or Caring for Opioid-dependent Pregnant Women 371 alcohol during pregnancy. 24 Screening should consist of verbal or written questioning about past and current alcohol, tobacco, illegal drug use, and the nonmedical use of prescription drugs. Urinary toxicology screening should not replace provider questioning as sporadic use may result in falsenegative results. 21 Moreover, standard urine toxicology screening typically identifies only morphine, codeine, and heroin derivatives, whereas semisynthetic or synthetic opioids such as oxycodone, buprenorphine, and fentanyl may require additional testing for identification. 21 Before performing drug screening, patient consent should be obtained and reasons for testing should be discussed in detail. Screening without consent or on the basis of clinician suspicion can impact patient-provider trust adversely and discourage women from continuing to seek prenatal care and other beneficial health care services. 25 Several substance use screening tools can be used for pregnant women and are intended to facilitate discussion on past and current drug and alcohol use ( Table 1) . Once substance use is identified, thorough substance use history should be taken, including the type of substances used, the route (inhalation, ingestion, or injection), the frequency, and the length of use as well as the substance use history of close family members and partners. 25 Risks of substance use on the mother (ie, HIV, HCV) and the baby (ie, low birth weight, NAS) should also be discussed with the patient, and referrals to addition medicine and/or drug and alcohol counseling should be initiated. Because of comorbid health concerns, patients should also be screened for additional psychosocial risk factors such as mental health disorders and intimate partner violence (Table 1) .
OPIOID MAINTENANCE THERAPY
For patients who meet the criteria for opioid dependence, treatment with opioid maintenance therapy is recommended. Opioid dependence is typically diagnosed after patients manifest signs and symptoms of physical withdrawal (ie, tachycardia, diarrhea, nausea, and vomiting) after drug cessation, rapid dose reduction, decreasing serum drug levels, and/or administration of an opioid antagonist. 26 Medically monitored conversion from illicit opioid use to opioid maintenance therapy decreases maternal and neonatal morbidity by providing a stable opioid dosing regimen, minimizing withdrawal, reducing risk-taking behavior, and decreasing the spread of HCV and HIV, and is associated with the improved utilization of health care services such as prenatal care. 23 Although closely monitored inpatient opioid detoxification is possible, opioid withdrawal has been associated with an increased risk of spontaneous abortion, preterm labor, fetal distress, and continued illicit drug use, and is not routinely recommended in pregnancy. 27, 28 In an evaluation of 95 women who elected inpatient opioid detoxification during pregnancy, 42 (44%) relapsed and used illicit drugs before delivery. 27 Methadone, a full m-opioid agonist, is the recommended standard treatment for OD pregnant women. 29 Methadone is available through federally licensed treatment facilities that dispense daily doses of methadone to patients in a closely monitored treatment setting. In 2002, the Food and Drug Administration approved buprenorphine (a partial m-opioid agonist) for the treatment of opioid addiction, and randomized controlled trials have established its safety in pregnancy. 30 An alternative, effective, evidence-based treatment option, buprenorphine, has important maternal benefits such as office-based practice availability and is associated with superior neonatal outcomes. [30] [31] [32] In a double-blind, randomized controlled trial, infants born to pregnant women treated with buprenorphine had a significantly shorter duration of treatment for NAS, required significantly lower doses of morphine when treated for NAS symptoms, and had a significantly shorter hospital stay than infants born to pregnant women treated with methadone. 30 Although effective for many OD women, buprenorphine is a partial opioid agonist and may have a decreased ability to alleviate cravings and withdrawal for women with severe addiction. 30, 33, 34 
TOBACCO USE
The majority of the OD pregnant women smoke during pregnancy, with a prevalence of 77% to 95%. [9] [10] [11] [12] Often confounding the impact of opioid use on adverse pregnancy outcomes, tobacco use during pregnancy is also associated with an increased risk of preterm birth, intrauterine growth restriction, and fetal death, and smoking cessation counseling should also be provided during each prenatal care visit. [35] [36] [37] The American College of Obstetricians and Gynecologists recommends the use of the ''5 A's,'' which consist of the following: (1) Ask pregnant patients about smoking at every obstetric visit; (2) Advise patients to stop smoking using a clear, strong, and personalized language; (3) Assess patients' willingness to stop smoking and motivations to quit; (4) Assist patients to stop smoking by providing strategies and resources; and (5) Arrange specific followup to track patients' progress. 38 Smoking cessation counseling has been significantly associated with both reduction and cessation of tobacco use during pregnancy. 39 
PSYCHIATRIC DISORDERS
In addition to comprehensive drug screening, all OD women should also be screened for co-occurring mental health disorders (Table 1 ). In a recent evaluation, 64.6% of the OD pregnant women endorsed symptoms related to a co-occurring psychiatric disorder such as anxiety (40.0%) and depression (32%), and 12.6% of the women reported suicidal thoughts in the past 30 days. 40 Women who reported psychiatric symptoms had a greater addiction severity, and were more likely to have deficits in family/social functioning, psychological
Caring for Opioid-dependent Pregnant Women 373 functioning, employment status, and medical impairment. 40 If a psychiatric disorder is identified, patients should be counseled on the risks and the benefits of various treatment options during pregnancy including pharmacotherapy, counseling, and behavioral interventions. Depending on the provider's experience, psychiatry or behavioral health specialists should be consulted to initiate a treatment program. 25 The use of pharmacologic treatments for psychiatric disorders should not be withheld because of pregnancy. In particular, selective serotonin reuptake inhibitors (SSRIs) can be used safely in pregnancy for moderate to severe depression and are compatible with breastfeeding. In large-cohort studies, SSRIs have not been associated with an elevated risk of teratogenicity with the exception of paroxetine, which has been associated with a small absolute increase in congenital heart defects. 41, 42 However, infants exposed to SSRIs in utero can exhibit an SSRI-induced withdrawal syndrome after birth that may mimic signs and symptoms of NAS. 43 Therefore, a comprehensive discussion of maternal and neonatal risks and benefits of the use of psychiatric pharmacotherapy in pregnancy should be conducted with each patient before initiation. 44 
INFECTIOUS DISEASES
All OD women should be screened for infectious diseases including HIV, HCV, and other sexually transmitted infections (ie, gonorrhea, chlamydia) during the initial prenatal care visit and repeated in the third trimester due to high rates of prostitution and the exchange of sex for drugs. 45, 46 HCV is especially prevalent due to high rates of intravenous opioid use, and education and counseling regarding HCV risk factors and transmission should be provided during prenatal care visits. 19, 45, 47, 48 Prenatal surveillance of HCV should include HCV RNA viral load testing and monitoring of liver transaminases to evaluate for evidence of liver inflammation and/or injury, and referral to hepatology to discuss the disease status and treatment options after delivery.
SOCIAL STRESSORS
Support from social workers and social service organizations are critical to providing comprehensive clinical care to patients with substance abuse. OD pregnant women are at a high risk for sexual violence, homelessness, prostitution, and incarceration, and many women do not have safe, drug-free living environments for themselves or their children. 24 Screening for a safe and supportive living environment should be performed privately (family members and partners outside of the room) during the initial prenatal care visit and throughout pregnancy. 25 Women who do not have a drug-free living environment should be referred to social services to assist with providing safe housing and/or case management services. 49 
PATIENT-PROVIDER RAPPORT
Developing and fostering a sense of trust, confidentiality, and a strong patient and provider rapport is critical to improving outcomes for OD women and their children. 21 Fears related to stigmatization and judgment from family, friends, and health care providers as well as involvement of child protective services prevent many women from seeking early or any prenatal care. 25 Open and honest communication about the importance of frequent and regular health care during pregnancy and the development of a trusting patient-provider relationship facilitates effective communication, decreases patient anxiety, and results in more productive clinical interactions. 21 Epidural or spinal anesthesia should be offered when necessary for intrapartum pain management as opioid maintenance therapy does not provide adequate pain relief. 24 The use of fetal scalp electrodes to monitor fetal heart rate during labor should be avoided in patients with HCV and HIV due to an increased risk of neonatal transmission. 50 Mixed agonistantagonists (eg, nalbuphine, butorphanol, pentazocine) should be avoided in all OD patients, and buprenorphine should be avoided in patients on methadone maintenance therapy as these agents may precipitate acute withdrawal. 24 Finally, pediatric care providers should be present at the delivery of all opioidexposed infants.
Intrapartum Care and Management

Postpartum Care and Management
OD patients may require more analgesia in the immediate postpartum period due to inadequate pain tolerance related to chronic opioid use. While oral and injectable nonsteroidal anti-inflammatory agents are often adequate after vaginal birth, additional doses of oral or intravenous short-acting opioids may be necessary for patients after cesarean section in addition to their methadone or buprenorphine maintenance therapy. An evaluation of OD women found a 70% increase in opiate analgesic requirements following cesarean delivery for women on methadone maintenance therapy and a 47% increase for women on buprenorphine maintenance therapy compared to matched controls. 51, 52 Postpartum patients should also be monitored for signs of oversedation (ie, respiratory depression, lethargy, aspiration) as maintenance therapy doses required during pregnancy may exceed the patients' therapeutic requirements in the postpartum period. 53 
NAS
All OD pregnant women should be counseled that infants chronically exposed to opioids in utero (licit or prescribed opioids, illicit opioids, or opioid maintenance therapy) are at risk for NAS. Characterized by hyperactivity of the central and the autonomic nervous systems, NAS symptoms may present any time in the first 2 weeks of life, but often occur within the first 3 to 4 days after birth. 54, 55 Symptoms such as excessive high-pitched cry, reduced quality and length of sleep, increased muscle tone and tremors are often accompanied by autonomic dysregulation (eg, sweating, yawning, and increased respiration) and gastrointestinal manifestations (eg, excessive sucking, poor feeding, vomiting and diarrhea). 55 Infants of OD women require close observation for the development of NAS for 3 to 4 days for short-acting opioids and 5 to 7 days for long-acting opioids, and withdrawal is commonly determined by assessing infants every few hours with a tool such as the Finnegan scale. 56 Pharmacologic intervention for withdrawal is required for 50% to 70% of the infants, most commonly with morphine or methadone. 57 Once the infant is on a stable dose of the selected opioid medication, the dose is slowly reduced over several days to weeks in a closely monitored medical withdrawal process. 55 Once infants are discharged, close follow-up with pediatric care providers familiar with caring for opioid-exposed children is recommended and all infants with opioid exposure should be referred to early intervention services to monitor infant development.
BREASTFEEDING
Breastfeeding is particularly important for chronically opioid-exposed newborns as it is the only intervention demonstrated to reduce NAS severity. Compared with formula-fed infants, infants fed breast milk are less likely to need pharmacologic treatment for NAS, and if treatment is
Caring for Opioid-dependent Pregnant Women 375 required, they require lower doses of morphine and thus have shorter hospital lengths of stay. 6, [58] [59] [60] Breastfeeding is also associated with stress reduction, increased maternal confidence, and enhanced mother-infant bonding. 61 Because of the significantly improved neonatal outcomes, OD women adherent to methadone or buprenorphine maintenance treatment should be encouraged to breastfeed, and education regarding the beneficial impact of breastfeeding on NAS should be incorporated into prenatal care counseling. 62 In the Guidelines for Breastfeeding and the Drug-Dependent Woman, the Academy of Breastfeeding Medicine outlines clear criteria for which OD women should receive breastfeeding support. 63 The American Academy of Pediatrics recommends breastfeeding for women taking methadone regardless of the maternal dose as very little methadone is present in breast milk (1% to 3% of the maternal weighadjusted dose). 62 Similarly, breastfeeding is recommended for women taking buprenorphine as low oral bioavailability results in minimal infant buprenorphine exposure through breast milk (<1% of the maternal weight-adjusted dose). 64 Clinicians should also be aware that breastfeeding is not contraindicated for women with HCV and caution should only be exercised if a mother develops an open lesion on her nipples or breast. 62 Breastfeeding, however, should be avoided in women who are actively using heroin and other illicit drugs as breastfeeding may cause tremors, restlessness, vomiting, respiratory suppression, lethargy, and poor feeding in infants.
CONTRACEPTION
OD women are at a significant risk for unplanned pregnancy, and postpartum contraception intention should be discussed throughout the prenatal care period. In an evaluation of 946 OD pregnant women, 89% of the pregnancies were unintended compared with 31% to 47% of the general population. 65 Long-acting reversible contraception such as intrauterine devices and subdermal implants should be encouraged over other methods due to significantly greater continuation rates when used for postpartum contraception. 66 To further reduce the risk of unplanned pregnancy, immediate postplacental intrauterine device placement or insertion of subdermal implants before patient discharge after delivery should also be considered to reduce barriers to long-acting reversible contraception use such as poor compliance with the postpartum visit. 67 
Conclusions
Pregnancy is a unique opportunity to change the lives of women with substance use disorders, and substantive improvement in maternal and neonatal outcomes requires engagement from a multidisciplinary team of invested health care providers. Although the complex psychiatric, social, and environmental factors faced by this population pose significant challenges to obstetric care providers, the development of a trusting, empathetic patient and provider relationship can significantly facilitate the ability to deliver the necessary prenatal and postpartum care services effectively. Patient and provider investment in optimizing maternal and neonatal health during pregnancy has the potential to reduce the morbidity of substance abuse and improve the future of OD women and their children.
